Top 5 Target	Count

VDCCs(Voltage-gated calcium channel)	1
L-type calcium channel(Voltage-gated L-type calcium channel)	1
IRAK4(Interleukin-1 receptor-associated kinase 4)	1
URAT1(Uric acid transporter 1)	1
GLP-1R(Glucagon-like peptide 1 receptor)	1

Drugs associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Amlodipine Benzoate

Target

VDCCs

Mechanism

VDCCs blockers

Active Org.

Guangzhou Yipinhong Pharmaceutical Co., Ltd. [+1]

Originator Org.

Azurity Pharmaceuticals, Inc.

Active Indication

Coronary Artery Disease [+2]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date08 Jul 2019

QinXiangQingJie

Target-

Mechanism-

Active Org.

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Originator Org.

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Active Indication

Respirovirus Infections [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

China

First Approval Date03 Jan 2009

Amlodipine Besylate

Target

L-type calcium channel

Mechanism

L-type calcium channel blockers

Active Org.

Pfizer Inc. [+11]

Originator Org.

Pfizer Inc.

Active Indication

Deglutition Disorders [+5]

Inactive Indication

Resistant hypertension

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United Kingdom

First Approval Date01 Mar 1989

Clinical Trials associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

CTR20243813

/ CompletedNot Applicable

评估受试制剂盐酸丙卡特罗颗粒（规格：50 μg）与参比制剂盐酸丙卡特罗干糖浆（Meptin®）（规格：0.005% (g/g)）在健康成年参与者空腹和餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验。

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study was conducted to evaluate the bioequivalence of the test product, Procaterol HCl Granules (strength: 50 μg), and the reference product, Procaterol HCl Dry Syrup (Meptin®) (strength: 0.005% (g/g)), in healthy adult participants under fasting and fed conditions.

主要试验目的：研究空腹和餐后状态下单次口服受试制剂盐酸丙卡特罗颗粒（规格：50 μg，广州一品红制药有限公司生产）与参比制剂盐酸丙卡特罗干糖浆（Meptin®，规格：0.005% (g/g)；大塚制药株式会社生产）在健康参与者体内的药代动力学特征，评价空腹和餐后状态口服两种制剂的生物等效性。次要试验目的：研究受试制剂盐酸丙卡特罗颗粒（规格：50 μg）和参比制剂盐酸丙卡特罗干糖浆（Meptin®）（规格：0.005% (g/g)）在健康参与者中的安全性。

[Translation]

Main purpose of the test: To study the single oral administration of the test preparation Procaterol Hydrochloride Granules (specification: 50 μg, produced by Guangzhou Yipinhong Pharmaceutical Co., Ltd.) and the reference preparation Procaterol Hydrochloride Dry Syrup (Meptin®, Specification: 0.005% (g/g); manufactured by Otsuka Pharmaceutical Co., Ltd.) in healthy participants to evaluate the bioequivalence of the two oral formulations in the fasting and postprandial states. Secondary trial purpose: To study the effects of the test preparation Procaterol Hydrochloride Granules (specification: 50 μg) and the reference preparation Procaterol Hydrochloride Dry Syrup (Meptin®) (Specification: 0.005% (g/g)) in healthy participants Security.

Start Date11 Nov 2024

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

CTR20241026

/ RecruitingPhase 2/3

评价AR882胶囊对比非布司他片治疗原发性痛风伴高尿酸血症患者的有效性和安全性的多中心、随机、双盲、平行对照、II/III期临床试验

[Translation] A multicenter, randomized, double-blind, parallel-controlled, phase II/III clinical trial to evaluate the efficacy and safety of AR882 capsules versus febuxostat tablets in the treatment of patients with primary gout and hyperuricemia

II期：（1）主要目的：探索AR882胶囊治疗原发性痛风伴高尿酸血症患者的有效性，以确定III期研究的给药方案。（2）次要目的：探索AR882胶囊在原发性痛风伴高尿酸血症患者中的安全性；基于群体药代动力学（PopPK）分析方法，探索AR882胶囊在原发性痛风伴高尿酸血症患者中的药代动力学（PK）特征；探索AR882和AR896的暴露与效应之间的关系。 III期：（1）主要目的：评价AR882胶囊治疗原发性痛风伴高尿酸血症患者的有效性（2）次要目的：评价AR882胶囊在原发性痛风伴高尿酸血症患者中的安全性；基于PopPK分析方法，探索AR882胶囊在原发性痛风伴高尿酸血症患者中的PK特征；探索AR882和AR896的暴露与效应之间的关系

[Translation]

Phase II: (1) Primary objective: To explore the efficacy of AR882 capsules in the treatment of patients with primary gout and hyperuricemia, so as to determine the dosing regimen for Phase III studies. (2) Secondary objectives: To explore the safety of AR882 capsules in patients with primary gout and hyperuricemia; to explore the pharmacokinetic (PK) characteristics of AR882 capsules in patients with primary gout and hyperuricemia based on the population pharmacokinetic (PopPK) analysis method; to explore the relationship between exposure and effect of AR882 and AR896. Phase III: (1) Primary objective: To evaluate the efficacy of AR882 capsules in the treatment of patients with primary gout and hyperuricemia (2) Secondary objectives: To evaluate the safety of AR882 capsules in patients with primary gout and hyperuricemia; to explore the PK characteristics of AR882 capsules in patients with primary gout and hyperuricemia based on the PopPK analysis method; to explore the relationship between exposure and effect of AR882 and AR896

Start Date19 Apr 2024

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

[+1]

CTR20230736

/ CompletedPhase 1

AR882胶囊在健康受试者中的单中心、随机、开放、单剂量、双周期、双交叉食物影响研究

[Translation] A single-center, randomized, open-label, single-dose, two-period, double-crossover food effect study of AR882 capsules in healthy subjects

（1）主要目的：评价食物（高脂高热量餐）对AR882胶囊（规格：25 mg）药代动力学的影响；（2）次要目的：评价广州瑞安博医药科技有限公司研制的AR882胶囊（规格：25 mg）在中国健康受试者中的安全性和耐受性；（3）探索性目的：评价食物（高脂高热量餐）对AR882胶囊（规格：25 mg）的药效动力学的影响。

[Translation]

(1) Primary objective: To evaluate the effect of food (high-fat, high-calorie meal) on the pharmacokinetics of AR882 capsules (specification: 25 mg); (2) Secondary objective: To evaluate the safety and tolerability of AR882 capsules (specification: 25 mg) developed by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. in healthy Chinese subjects; (3) Exploratory objective: To evaluate the effect of food (high-fat, high-calorie meal) on the pharmacodynamics of AR882 capsules (specification: 25 mg).

Start Date23 Sep 2023

Sponsor / Collaborator

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

0 Patents (Medical) associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Literatures (Medical) associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Zhongyao Xinyao Yu Linchuang Yaoli

Determination of ephedrine hydrochloride and pseudoephedrine hydrochloride in Fuganlin oral liquid by HPLC

Author: Zhang, Li ; Chen, Yiwen ; Zeng, Yongchang ; Zeng, Xiaoyan

Objectives: To establish a HPLC method to determine the content of ephedrine hydrochloride and pseudoephedrine hydrochloride in Fuganlin oral liquidMethods: The chromatog. conditions was as follows: Phenomenex Synergi Polar-RP column (250 mm × 4.6 mm, 4μm), methanol-0.092% phosphoric acid solution (containing 0.04% triethylamine and 0.02% di-n-butylamine) (1.5:98.5) as the mobile phase, flow rate being 1.0 mL · min^-1, detection wavelength set as 210 nm.Results: The linear range of ephedrine hydrochloride and pseudoephedrine hydrochloride was 1-100μg · mL^-1, and the average recovery (n = 6) was 97.43% (RSD = 0.80%) and 98.59% (RSD = 1.77%) resp.Conclusions: The method is simple, accurate and reliable, and can be used for the simultaneous determination of ephedrine hydrochloride and pseudoephedrine hydrochloride, which will provide a scientific basis for quality evaluation of Fuganlin oral liquid

Heilongjiang Yiyao

Process conditions screening of Compound Amino Acid Injection (18AA)

Author: Zhuang, Manxian ; Zhou, Cuilan

Objective: To establish the process conditions which are suitable for the large-scale production of Compound Amino Acid Injection (18AA), and to ensure the stability of product quality.Methods: Through the screening of the production process conditions which can affect the quality of Compound Amino Acid Injection (18AA), and to determine the conditions of the optimal dosage of activated carbon, sterilization time, sterilization temperature and whether nitrogen.Results: The optimal conditions were as follow: filled with nitrogen, the activated carbon dosage of 0.05%, the sterilization temperature of 121°C and the sterilization time of 10 min.Conclusions: The established process conditions are suitable for the production of this product, which is reasonable and scientific.

Guangdong Huagong

Study on the Inclusion Process of Volatile Oil in Qinxiang Qingjie Oral Liquid

Author: Kang Xiaodong ; Zhang Chongjing ; Li Minghui ; Li Yongwei ; Li Haibo

Objective: To study the best inclusion process of the pogostemon cablin essential oil from Qinxiang Qingjie oral liquid with hydroxypropyl betacyl dextrin(HP-β-CD).Methods: The process conditions were screened by determining the inclusion rate of volatile oils and the yield of inclusion compoundOrthogonal design test was used to optimize the inclusion process, and the structure of the inclusion compound was characterized by GC, X-ray diffraction and IR.Results: the best preparation process of inclusion compound was as follows: the inclusion temperature was 35 °C, the inclusion time was 2.5 h, and the volatile oil of patchouli♂HP-β-CD=1♂12.The inclusion compound was formed and the composition of the volatile oil had no obvious change after inclusion.Conclusion: According to the optimized process, The complex prepared under the optimized process is stable, and that has the advantages of the highest inclusion rate, stable inclusion process and easily soluble in oral liquid

100 Deals associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

100 Translational Medicine associated with Guangzhou Yipinhong Pharmaceutical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Phase 1 Clinical

Phase 3 Clinical

NDA/BLA

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Amlodipine Besylate ( L-type calcium channel )	Hypertension More	Approved
QinXiangQingJie	Respirovirus Infections More	Approved
Amlodipine Benzoate ( VDCCs )	Angina Pectoris More	NDA/BLA
Pozdeutinurad ( URAT1 )	Hyperuricemia More	Phase 3 Clinical
APH01727 ( GLP-1R )	Diabetes Mellitus, Type 2 More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis